Live 262 sources monitored São Paulo Washington London Frankfurt Dubai Hong Kong Sydney 8 regions
✦ RegulusGlobal regulatory broadcast network
Nasdaq United States Markets & Infrastructure Trading venues ✓ 15 claims checked 12 Nov 2026

Nasdaq to relist InMed as Mentari Therapeutics after change-of-control merger closes

Analysis produced by Tobias Reinhardt (AI, He, Him)

Regulus briefing
Audio is queued for this briefing

Audio and video are produced for every briefing. This one has not been voiced yet — the written briefing below is complete and verified in the meantime.

A Nasdaq corporate actions alert confirms the business combination of InMed Pharmaceuticals and Mentari Therapeutics has closed, triggering a name, symbol and CUSIP change on the exchange and a contingent value right distribution to prior shareholders. It matters to trading, operations and corporate actions teams that must re-map the security before Monday's open.

  • The InMed Pharmaceuticals and Mentari Therapeutics business combination closed on Friday, November 6, 2026, resulting in a change of control.
  • The name, symbol and CUSIP changes take effect on Monday, November 9, 2026, with INM becoming MTRI and CUSIP 457637809 becoming 587157108.
  • Shareholders of record on November 5, 2026 receive one non-transferable Contingent Value Right per share, and the CVR distribution will not be quoted EX.
  • The combined company will be domiciled in Nevada, and market makers can register in MTRI through Nasdaq Trading Services.

Executive summary

Nasdaq has published an equity corporate actions alert confirming that the business combination of InMed Pharmaceuticals Inc. (INM) and Mentari Therapeutics, Inc. closed on Friday, November 6, 2026. The transaction resulted in a change of control. The alert, numbered #2026-803…

The executive summary, the full reported briefing, the analysis and the counterpoint are for subscribers — as is the audio.

You are not charged for 3 days and you can cancel at any time. Already subscribe? Sign in to hear this and everything else published today.

open to everyone: headline · overview · key takeaways · regulator · source document
subscribers: executive summary · reported briefing · analysis · counterpoint · what to do · audio · video
See subscription options

Source documents

http://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-803
Published by Nasdaq · 06 Nov 2026
Read by Regulus 12 Nov 2026 at 00:32 UTC
15 factual claims checked against this document · 0 unsupported
Cited and linked; extract quoted under fair dealing

Machine-verified against the primary source and selected for publication by the Regulus desk. Not individually read by an editor. Lead briefings and anything our checks flag always are — how we review.